Shots:

• The P-III (ATTRibute-CM) study evaluates acoramidis (800mg) vs PBO in a ratio (2:1) in 632 patients with symptomatic ATTR-CM
• The study failed to meet its 1EPs i.e., @12mos., the therapy showed mean decline in 6MWD with baseline eGFR ≥ 30 mL/min/1.73m2 while decline observed in both arms was similar to healthy elderly adults and > 40-meter annual declines in prior untreated ATTR-CM cohorts
• The therapy showed improvements in KCCQ-OS, QoL measurement, NT-proBNP, and increased serum TTR level @12mos., was generally well-tolerated & no safety signals of clinical concern were observed. Additionally, the company is expected to deliver other clinical-stage pipeline catalysts in 2022

Ref: BridgeBio | Image: BridgeBio